Company news
Radiopharm Theranostics Limited news in 2026
Radiopharm Theranostics Limited's news releases, calls and decks from 2026, newest first.
RAD completes A$12.5 M placement and launches A$6 M SPP
July 24, 2026
Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
July 22, 2026
RAD Achieves Partial Response in Phase 1 Trial of RAD204
July 21, 2026
Radiopharm Theranostics Reports Business Update
April 23, 2026
Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026
April 20, 2026
Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases
April 16, 2026
RAD Completes Enrollment in Phase 2b Trial of RAD 101
April 15, 2026
Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
April 8, 2026
RAD202 Phase 1 HEAT Trial Advances to Dose Level 3
April 7, 2026
Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.
April 7, 2026
Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer
March 27, 2026
RAD Doses First Patient in RAD 402 Phase 1 Clinical Study
March 26, 2026
Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases
March 24, 2026
RAD101 2nd interim Ph.2b data - 90% achieve primary endpoint
March 23, 2026
Half Year Report and Appendix 4D 31 December 2025
February 27, 2026
Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
February 25, 2026
Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)
February 24, 2026
RAD Doses First Patient in 177Lu-BetaBart (RV-01) Study
February 23, 2026
Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
January 28, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 27, 2026
Presenting on Emerging Growth Conference 89 Day 2 on January 22; Register to live stream
January 21, 2026
Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live stream
January 20, 2026
RAD Increases Ownership in Radiopharm Ventures to 87.5%
January 12, 2026
Decks in 2026
- Investor Presentation (October 2026)
Investor deck · 38 slides · October 2026
- Investor Presentation (July 2026)
Investor deck · 31 slides · Jul 24, 2026
- Investor Presentation (June 2026)
Investor deck · 41 slides · June 2026